{"id":"W4410809998","doi":"10.1200/jco.2025.43.16_suppl.7546","title":"DREAMM-7 study of belantamab mafodotin plus bortezomib and dexamethasone (BVd) vs daratumumab plus bortezomib and dexamethasone (DVd) in relapsed/refractory multiple myeloma (RRMM): A subgroup analysis in patients (pts) with high-risk cytogenetic (HRC) features.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Subgroup analysis; Oncology; Refractory (planetary science); Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002496442,0.001120884,0.00303764,0.0003999729,0.0002188678,0.0008583062,0.00106635,0.0009079458,0.003321839],"category_scores_gemma":[0.001962434,0.0005177181,0.004075265,0.0004654288,0.0005649563,0.0006776474,0.0006249254,0.002707993,0.0005505264],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009747437,"about_ca_system_score_gemma":0.00107706,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009982659,"about_ca_topic_score_gemma":0.002850644,"domain_scores_codex":[0.9988322,0.0007655211,0.00007487772,0.0001368707,0.00007953425,0.0001110285],"domain_scores_gemma":[0.9988561,0.0003566025,0.0002931366,0.00009259199,0.00005862084,0.0003430226],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9695917,0.002629008,0.003406706,0.0006897339,0.006431814,0.00004889787,0.00006152845,0.0007590721,0.002353832,0.0001038857,0.000725934,0.01319777],"study_design_scores_gemma":[0.7907425,0.1779478,0.0175393,0.0001191494,0.008584836,0.0001732399,0.0001141402,0.001330896,0.0008941031,0.0003500046,0.002158956,0.00004502035],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9880414,0.006149359,0.0004521268,0.000548742,0.0002830849,0.001250848,0.001792378,0.00004447097,0.001437698],"genre_scores_gemma":[0.9910061,0.002281205,0.001059299,0.0006713815,0.000284942,0.001131552,0.001952415,0.00002009399,0.001593071],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003321839,"threshold_uncertainty_score":0.01320255,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03635375651785969,"score_gpt":0.3805149328188414,"score_spread":0.3441611763009816,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}